Get the Stockscreener App
1.43
2.88%
0.04
After Hours:
1.39
-0.04
-2.80%
Acrivon Therapeutics Inc stock is traded at $1.43, with a volume of 331.39K.
It is up +2.88% in the last 24 hours and up +7.52% over the past month.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
See More
Previous Close:
$1.39
Open:
$1.41
24h Volume:
331.39K
Relative Volume:
0.44
Market Cap:
$44.84M
Revenue:
-
Net Income/Loss:
$-69.00M
P/E Ratio:
-0.5144
EPS:
-2.78
Net Cash Flow:
$-55.26M
1W Performance:
+5.93%
1M Performance:
+7.52%
6M Performance:
-73.76%
1Y Performance:
-82.92%
1-Day Range:
$1.34
$1.47
1-Week Range:
$1.34
$1.495
52-Week Range:
$1.05
$10.16
Acrivon Therapeutics Inc Stock (ACRV) Company Profile
Name
Acrivon Therapeutics Inc
Sector
Industry
Phone
617-207-8979
Address
480 ARSENAL WAY, SUITE 100, WATERTOWN
Compare ACRV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACRV
Acrivon Therapeutics Inc
|
1.43 | 43.58M | 0 | -69.00M | -55.26M | -2.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Acrivon Therapeutics Inc Stock (ACRV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-05-25 | Resumed | Piper Sandler | Overweight |
| Jan-31-25 | Initiated | KeyBanc Capital Markets | Overweight |
| Sep-16-24 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Apr-29-24 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Mar-01-24 | Initiated | JMP Securities | Mkt Outperform |
| Dec-15-23 | Resumed | Jefferies | Buy |
| Oct-05-23 | Initiated | Maxim Group | Buy |
| Jun-02-23 | Initiated | Oppenheimer | Outperform |
| May-08-23 | Initiated | BMO Capital Markets | Outperform |
| Apr-27-23 | Initiated | Ladenburg Thalmann | Buy |
| Apr-20-23 | Initiated | H.C. Wainwright | Buy |
| Dec-12-22 | Initiated | Cowen | Outperform |
| Dec-12-22 | Initiated | Jefferies | Buy |
| Dec-12-22 | Initiated | Piper Sandler | Overweight |
View All
Acrivon Therapeutics Inc Stock (ACRV) Latest News
How high can Acrivon Therapeutics Inc. stock price go in 2025Free Group Entry - Newser
Acrivon Therapeutics Inc. Stock Analysis and ForecastAccelerated earnings growth - jammulinksnews.com
What analysts say about Acrivon Therapeutics Inc. stockRapid wealth creation - jammulinksnews.com
Is Acrivon Therapeutics Inc. a good long term investmentHigh-octane investment gains - jammulinksnews.com
Here's Why We're Watching Acrivon Therapeutics' (NASDAQ:ACRV) Cash Burn Situation - Yahoo Finance
What drives Acrivon Therapeutics Inc. stock priceConsistently superior profits - PrintWeekIndia
Is Acrivon Therapeutics Inc. stock a good hedge against inflationSolid Return Trade Selections - beatles.ru
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Average Rating of “Buy” from Analysts - Defense World
Analysts Set Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Target Price at $17.71 - Defense World
What makes Acrivon Therapeutics Inc. stock price move sharplyFree Stock Market Real-Time Monitoring - Newser
Cantor Fitzgerald sets Acrivon stock to Overweight on AP3 platform - MSN
How Acrivon Therapeutics Inc. stock performs during market volatilityAlpha Stock Ideas - Newser
Endometrial Cancer Clinical Trial Pipeline Insights: 50+ Companies Shaping Future Treatment Paradigms | DelveInsight - GlobeNewswire Inc.
Why Acrivon Therapeutics Inc. stock attracts strong analyst attentionExpert Backed Predictions - Newser
(ACRV) Investment Analysis and Advice - news.stocktradersdaily.com
Acrivon Therapeutics (NASDAQ:ACRV) Trading 0.7% Higher – Still a Buy? - Defense World
Acrivon Therapeutics, Inc.(NasdaqGM: ACRV) dropped from S&P Global BMI Index - MarketScreener
Learn to Evaluate (ACRV) using the Charts - news.stocktradersdaily.com
Acrivon Therapeutics Holds Annual Stockholders Meeting - TipRanks
Analysts Offer Predictions for ACRV FY2026 Earnings - Defense World
Long Term Trading Analysis for (ACRV) - news.stocktradersdaily.com
Nuveen Asset Management LLC Sells 12,377 Shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV) - Defense World
Northern Trust Corp Has $706,000 Stock Position in Acrivon Therapeutics, Inc. (NASDAQ:ACRV) - Defense World
Acrivon Therapeutics Inc Stock (ACRV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.97%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):